1. health and fitness
2. disease
3. aids and hiv

9–11 October 2014
Sheraton Frankfurt Airport Hotel &
Conference Center, Frankfurt, Germany
FINAL PROGRAMME
CONTENTS
WELCOME
3
SCIENTIFIC COMMITTEE
4
PROGRAMME OVERVIEW
5
CONGRESS APP
6
KEYPADS
8
JOIN THE CONVERSATION
9
SCIENTIFIC PROGRAMME
10
GENERAL INFORMATION
17
WELCOME RECEPTION, LUNCHES AND REFRESHMENTS
22
SCIENTIFIC PROGRAMME INFORMATION
23
VENUE MAP
25
CHAIRS’ BIOGRAPHIES
26
SCIENTIFIC COMMITTEE BIOGRAPHIES
28
SPEAKER BIOGRAPHIES
37
POSTER CATEGORIES
54
POSTER PRESENTATIONS
55
MAJORS SPONSORS
61
PRE-CONGRESS WORKSHOP SPONSOR
65
EXHIBITOR
66
OTHER SPONSORS
66
AUTHOR INDEX
67
2
WELCOME
We are delighted to welcome you to Frankfurt for the third Viral Hepatitis Congress. We hope
over the coming days you will enjoy a high-quality and relevant scientific programme,
augmented by extremely popular, innovative and interactive discussion sessions. Last year we
received over 200 questions during the Congress period and we hope that this year we will see a
similar level of scientific exchange. During the programme we have increased the time allocated
for questions and discussion to allow plenty of time for us to interact.
In 2014, we will engage our online audience by welcoming questions from all over the world via
email and Twitter and look forward to connecting with people that are unable to attend this
year. We have also endeavoured as a Congress to go ‘paper-free’ and this year you will find all
the Congress materials, including instructions on how to download the Congress app, within a
portal on the Congress website (www.viral-hep.org).
If you attended the Congress last year you will have experienced the intimate nature of the
meeting. We hope that this relaxed environment provides you with a platform to meet
colleagues, absorb clinical developments and listen to international experts who are here to
share their experiences with you.
For this event we will be welcoming back some colleagues from previous Congresses and in
addition, some new presenters. In particular, we are honoured to have Dr Harvey J Alter present
a Special Opening Lecture. We would like to thank all our Scientific Committee, presenters and
industry partners for their continued support.
This year has seen great changes in the field of viral hepatitis, with many drugs arriving and
various treatment options for our patients. In this rapidly evolving environment, it is more
important than ever to sustain a forum where the wealth of data can be put into a practical
perspective for our colleagues. This year we will digest the latest data from a broad range of
sources, examine the new treatments, and translate this array of information for you, our
audience.
We hope you enjoy the meeting and we look forward to seeing you.
Professor Ira M Jacobson
Professor Stefan Zeuzem
Co-Chairs, Viral Hepatitis Congress
3
SCIENTIFIC COMMITTEE
CO-CHAIRS
Ira M Jacobson
Weill Medical College of Cornell University, New York, USA
Stefan Zeuzem
J.W. Goethe-University Hospital, Frankfurt am Main, Germany
SCIENTIFIC COMMITTEE
Nezam Afdhal
Harvard Medical School, Boston, USA
Antonio Craxì
University of Palermo, Palermo, Italy
Geoffrey Dusheiko
Royal Free Hospital, London, UK
Jordan Feld
University of Toronto, Ontario, Canada
Graham R Foster
Queen Mary, University of London, London, UK
Patrick Marcellin
University of Paris, Paris, France
Hendrik Reesink
Academic Medical Centre, Amsterdam, The Netherlands
Jürgen Rockstroh
University of Bonn, Bonn, Germany
Heiner Wedemeyer
Hanover Medical School, Hanover, Germany
ACADEMIC SPONSORS
4
PROGRAMME OVERVIEW
Thursday 9 October 2014
Friday 10 October 2014
Saturday 11 October 2014
08.00
08.00
09.00
10.00
INDUSTRY-SPONSORED
SYMPOSIUM
INDUSTRY-SPONSORED
SYMPOSIUM
REFRESHMENTS & EXHIBITION
REFRESHMENTS & EXHIBITION
09.00
10.00
KEYNOTE LECTURE
11.00
12.00
11.00
INDUSTRY
PRE-CONGRESS
WORKSHOP
HEPATITIS C TREATMENT:
THE WAY FORWARD
REFRESHMENTS & EXHIBITION
13.00
DEBATING THE
TREATMENT OF HCV
12.00
LUNCH & EXHIBITION
13.00
THE EFFECT OF HEPATITIS B
AND C OUTSIDE THE LIVER
14.00
KEYNOTE LECTURE
& CLOSING
15.00
OPENING &
SPECIAL OPENING LECTURE
14.00
15.00
SCREENING AND
DIAGNOSIS: WHAT YOU
NEED TO KNOW
KEYNOTE LECTURE
LUNCH & EXHIBITION
REAL-LIFE EXAMPLES,
A CASE-STUDY SESSION
ORAL PRESENTATION
REFRESHMENTS & EXHIBITION
16.00
REFRESHMENTS & EXHIBITION
16.00
HEPATITIS C TREATMENT:
THE STORY SO FAR
HEPATITIS B TREATMENT
17.00
17.00
REFRESHMENTS & EXHIBITION
18.00
INDUSTRY-SPONSORED
SYMPOSIUM
19.00
REFRESHMENTS & EXHIBITION
18.00
INDUSTRY-SPONSORED
SYMPOSIUM
19.00
WELCOME RECEPTION
20.00
20.00
5
CONGRESS APP
USE THE FREE CONGRESS MOBILE APP TO ACCESS KEY PROGRAMME
INFORMATION AND PLAN YOUR MEETING ON THE GO!
The Congress app provides vital event detail at your fingertips 24/7 and is available to download
to all smartphones and tablets (iOS/Android). A Web version is also available for Blackberry and
other mobile platforms.
The scientific programme, all abstracts and faculty biographies are accessible through the app.
You can also connect with colleagues and send private messages. It’s easy to use, simply log-in
and follow the details on the following page.
Other key features include:
•
•
Sign in to update your schedule and access the latest version from any mobile device
Receive Congress update notifications
DOWNLOADING THE VIRAL HEPATITIS CONGRESS APP
This app is compatible with iPhone, iPod, iPad, Android and BlackBerry.
1. Open your web browser and navigate to the URL: www.viral-hep.org/app
2. Follow the instructions below for your device:
Android
•
Press the menu button
and select bookmarks
•
Select the top left
thumbnail labelled Add
•
Add shortcut to Home
•
Press and hold Home
screen and select
iOS
•
To add the app to your
Home Screen, tap the
following icon:
•
Followed by the Add to
Home Screen icon:
Shortcuts
•
After selecting
Shortcuts from the
menu, select Bookmark
•
Installation complete!
•
Tap the word Add in
the top right
•
Installation complete!
BlackBerry
•
Press the following
button:
•
Then, to add a shortcut
to the home screen,
press Add to Home
Screen
•
Or, to add a shortcut to
your favourites view,
press Mark as Favourite
•
Installation complete!
This function is only available for
BlackBerry 9000 series or higher.
6
CONGRESS APP
INTERACTING WITH OTHER PARTICIPANTS
The Viral Hepatitis Congress app allows you to communicate with other participants through
both public and private messaging by using the Network function.
Please note, if you did not provide your email as part of the registration process, this will not
work. Please visit the registration desk to provide your email address and have your account
activated.
To access the Network function:
•
Tap the Network icon:
•
Enter your username and password:
Username: [your email address]
Password: vhc14
•
You can send public messages to the Congress ‘message wall’ by tapping the button
Public Message. All app users will be able to see ‘public messages’. The Organising
Secretariat will monitor and moderate comments, as required.
•
You can send private messages by tapping the following icon to view the list of
participants (who have opted to use the app):
Find the person you wish to interact with and send them a message.
•
You can receive and reply to private messages by tapping the following icon:
•
By visiting your profile you can log out and change your password.
7
KEYPADS
The Congress is using a keypad system for participants
to interact with the faculty during the main plenary
sessions. A keypad is available to every participant on
entry to the main auditorium. Keypads allow voting,
messaging, and submitting questions via text to the
session Chairs.
VOTING
When indicated by a member of the faculty, a question
will appear on the main projection screen with
multiple choice answers. To vote, you should press the
corresponding keyboard button on your handset
within the time limit.
SUBMIT A QUESTION
At any time you may text a question to the Chairs using the full QWERTY keyboard. When you
are ready to submit your question, press the green button on the keypad. Alternatively, email us
at [email protected] with QUESTION in the subject line. During the interactive Q&A
periods, you can also ask questions by going to the nearest aisle microphone.
RETURN YOUR KEYPAD
At the end of the session, please leave your keypad in the auditorium. The keypads are alarmed
and the alarm will activate if removed from the meeting area.
8
JOIN THE CONVERSATION
ASK US A QUESTION
Whatever your experience, if you have a question, we’re ready to listen. You can do this during
sessions by using the keypads. If you would like to email us, send your questions to
[email protected] with QUESTION in the subject header.
SPEAK TO YOUR FRIENDS AND COLLEAGUES
Take this opportunity to network, we have allowed plenty of breaks in the programme so you
can catch up with your colleagues from all over the world. Feeling social? Join us for informal
drinks at the poster reception on Thursday 9 October from 19.00 to 20.00.
GET DIGITAL
Tweet, message, post and comment; there are loads of ways to connect with us online.
The official hashtag for the meeting is #vhep14 and make sure you follow us @Viralhep2014
where you will find plenty of up-to-the-minute news over on our Twitter feed. Join in and let us
know who you are and what's on your mind.
9
PROGRAMME – THURSDAY 9 OCTOBER
11.30
Industry-sponsored pre-Congress workshop
12.30
Refreshments, posters and exhibition opening
13.00
Opening
Ira M Jacobson (New York, USA); Stefan Zeuzem (Frankfurt, Germany)
Special Opening Lecture
Chairs:
Ira M Jacobson (New York, USA); Stefan Zeuzem (Frankfurt, Germany)
13.10
Keeping blood safe – a global challenge
OL
OLCH
OL1
Harvey J Alter (Bethesda, USA)
Screening and diagnosis: what you need to know
Chairs:
Ira M Jacobson (New York, USA); Stefan Zeuzem (Frankfurt, Germany)
13.40
Non-invasive assessment of liver fibrosis
O11
O11CH
O111
Nezam Afdhal (Boston, USA)
14.00
HCV genome sequencing: what the clinician needs to know
O112
Christoph Sarrazin (Frankfurt, Germany)
14.20
Interactive Q&A and panel discussion
Keynote Lecture and oral presentation
Chairs:
Ira M Jacobson (New York, USA); Stefan Zeuzem (Frankfurt, Germany)
14.40
The risk of developing cancer following successful treatment for hepatitis
KL1
KL1CH
KL1
Massimo Colombo (Milan, Italy)
15.10
Association of the −515A>G CDC6 polymorphism with risk to develop
hepatocellular carcinoma in patients with chronic hepatitis C
O113
M Elhendawy, F Finkelmeier, V Köberle, S Susser, A Abou El Azm, G El Kassa,
S Zeuzem, C Sarrazin, O Waidmann and A Piiper (Tanta, Egypt)
15.25
Refreshments, posters and exhibition
Author underlined indicates presenting author.
10
PROGRAMME – THURSDAY 9 OCTOBER
Hepatitis C treatment: the story so far
Chairs:
Hendrik Reesink (Amsterdam, The Netherlands); Uwe Siebert (Hall in Tirol,
Austria)
15.45
Drug availability: what, where, and when?
O12
O12CH
O121
Graham R Foster (London, UK)
16.05
Global differences: what can we learn from HIV?
O122
Robert Schooley (San Diego, USA)
16.25
Boceprevir and telaprevir: what have we learned?
O123
Marc Bourlière (Marseille, France)
16.45
Interactive Q&A and panel discussion
17.05
Refreshments, posters and exhibition
17.30
Industry-sponsored symposium
19.00
Welcome Reception, posters and exhibition
11
PROGRAMME – FRIDAY 10 OCTOBER
08.30
Industry-sponsored symposium
10.00
Refreshments, posters and exhibition
Hepatitis C treatment: the way forward
Chairs:
Maria Butí (Barcelona, Spain); Patrick Marcellin (Paris, France)
10.20
With interferon
O21
O21CH1
O211
Michael Fried (Chapel Hill, USA)
10.40
Simeprevir versus telaprevir in combination with pegylated interferon
and ribavirin in HCV genotype 1-infected patients: the Phase III ATTAIN
study
O212
H Hinrichsen, K Reddy, F Zoulim, O Weiland, A Horban, G Taliani, C Stanciu,
F Villamil, J George, E Dammers, M Fu, D Kurland, O Lenz,
S Ouwerkerk-Mahadevan, T Verbinnen, M Schlag, W Jessner and S Zeuzem
(Kiel, Germany)
10.55
Daclatasvir vs telaprevir in combination with peginterferon alfa/ribavirin
in treatment-naïve patients with HCV genotype 1: phase 3 COMMAND-3
results
O213
I Jacobson, S Zeuzem, R Flisiak, B Knysz, S Lueth, D Zarebska-Michaluk,
E Janczewska, P Ferenci, M Diago, A Zignego, R Safadi, Y Baruch,
D Abdurakhmanov, S Shafran, D Thabut, R Bruck, A Gadano, A Thompson,
J Kopit, F McPhee, T Michener, E Hughes, P Yin and S Noviello
(New York, USA)
11.10
Without interferon, with nucs
O214
David Nelson (Gainesville, USA)
11.30
Interactive Q&A and panel discussion
Author underlined indicates presenting author.
12
PROGRAMME – FRIDAY 10 OCTOBER
Hepatitis C treatment: the way forward (continued)
Chairs:
Michael Fried (Chapel Hill, USA); David Nelson (Gainesville, USA)
11.45
Interferon-free Direct-Acting Antiviral (DAA) regimens without
nucleoside (tide) analogs for treatment of chronic hepatitis C
O21
O21CH2
O215
Kris V Kowdley (Seattle, USA)
12.05
Treating decompensated cirrhotics
O216
Geoffrey Dusheiko (London, UK)
12.25
Treating patients before and after transplant
O217
Marina Berenguer (Valencia, Spain)
12.45
New DAAs and drug–drug interactions
O218
David Burger (Nijmegen, The Netherlands)
13.05
Interactive Q&A and panel discussion
13.20
Lunch, posters and exhibition
Real-life examples, a case-study session
Chairs:
Geoffrey Dusheiko (London, UK); Robert Schooley (San Diego, USA)
14.20
Real-life examples: transplantation
O22
O22CH
O221
Marina Berenguer (Valencia, Spain)
14.40
Real-life examples: HIV co-infection
O222
Jürgen Rockstroh (Bonn, Germany)
15.00
Real-life examples: renal impairment
O223
Paul Martin (Miami, Florida)
15.20
Interactive Q&A and panel discussion
15.40
Refreshments, posters and exhibition
13
PROGRAMME – FRIDAY 10 OCTOBER
Hepatitis B treatment
Chairs:
Nezam Afdhal (Boston, USA); Paul Martin (Miami, Florida)
16.00
Long-term persistence of patient-derived hepatitis B virus infection in 3D
microfluidic primary hepatocyte cultures
O23
O23CH
O231
S Wai, E Large, D Hughes, E Sceats, M Lussignol, M Catanese, M Thursz and
M Dorner (London, UK)
16.15
Entecavir vs the tenofovirs (TDF and TAF)
O232
Harry Janssen (Toronto, Canada)
16.35
Interferon and add-on strategies in the treatment of chronic hepatitis B
O233
Patrick Marcellin (Paris, France)
16.55
Preventing reactivation in immunosuppressive and chemotherapy patients
O234
Maria Butí (Barcelona, Spain)
17.15
An investigation of genome-wide promoter region CpG island
methylation profiles in patients with chronic hepatitis B virus infection
O235
M Kgatle, H Hairwadzi and P Vivekanandan (Cape Town, South Africa)
17.30
Interactive Q&A and panel discussion
17.50
Refreshments, posters and exhibition
18.20
Industry-sponsored symposium
19.50
Sessions close
Author underlined indicates presenting author.
14
PROGRAMME – SATURDAY 11 OCTOBER
08.30
Industry-sponsored symposium
10.00
Refreshments, posters and exhibition
Keynote Lecture
Chairs:
Antonio Craxì (Palermo, Italy); Jordan Feld (Toronto, Canada)
10.20
Understanding HCV disease progression and the associated cost
KL2
KL2CH
KL2
Uwe Siebert (Hall in Tirol, Austria)
Debating the treatment of HCV
Chairs:
Antonio Craxì (Palermo, Italy); Jordan Feld (Toronto, Canada)
10.50
Treating genotypes 3 and 4 patients with/without IFN or a second DAA
O31
O31CH
O311
Tarik Asselah (Paris, France)
11.10
How should we monitor patients after SVR?
O312
Ira M Jacobson (New York, USA)
11.30
How do we treat acute HCV when we don’t have any trial data?
O313
Heiner Wedemeyer (Hanover, Germany)
11.50
HCV contributes to the aggravation suppressive activity of natural
regulatory T cells and induces the emergence of type 1 regulatory T cells
O314
L Ouaguia, O Morales, C Wychowski, A Carpentier, L Aoudjehane,
J Dubuisson, Y Calmus, Y de Launoit, F Conti and N Delhem (Lille, France)
12.05
Interactive Q&A and panel discussion
12.25
Lunch, posters and exhibition
Author underlined indicates presenting author.
15
PROGRAMME – SATURDAY 11 OCTOBER
The effect of hepatitis B and C outside the liver
Chairs:
Kris V Kowdley (Seattle, USA); Christoph Sarrazin (Frankfurt, Germany)
13.25
HCV and insulin resistance
O32
O32CH
O321
Francesco Negro (Geneva, Switzerland)
13.45
HCV and lymphomas
O322
Jordan Feld (Toronto, Canada)
14.05
Vasculitis and its relationship to hepatitis C
O323
Francesco Dammacco (Bari, Italy)
14.25
Interactive Q&A and panel discussion
Keynote Lecture
Chairs:
Kris V Kowdley (Seattle, USA); Christoph Sarrazin (Frankfurt, Germany)
14.45
Unresolved issues in HCV biology
KL3
KL3CH
KL3
Darius Moradpour (Lausanne, Switzerland)
15.15
Closing remarks
Stefan Zeuzem (Frankfurt, Germany)
16
GENERAL INFORMATION
ACCESSIBLE FACILITIES
The venue is equipped with facilities for individuals with reduced mobility. Bathrooms are
available on Level E1, directly opposite the registration desk.
BUSINESS CENTRE
Facilities are available on the level above the Congress Center in the lobby of the hotel (Level
E2).
CAR PARKING
Public parking facilities are located below the hotel in the garages P2 and P3 (up to 30 spaces
available). Parking costs €4.40 per hour up to a maximum of €25 per day. Please note, the hotel
does not accept any reservations for parking. Additional parking is available at the airport for €4
per hour.
CASH FACILITIES
The nearest ATM facilities are located in Terminal 1 of the airport, which is reached via a
covered walkway from the hotel lobby.
CLOAKROOM
Free cloakroom facilities will be available throughout the Congress at the registration desk,
during the following times:
Thursday 9 October 2014
10.00–20.00
Friday 10 October 2014
08.00–20.00
Saturday 11 October 2014
08.00–16.00
Neither the Congress Center nor the Organising Secretariat can accept responsibility for any loss
or damage to items left in the cloakroom or meeting rooms.
17
GENERAL INFORMATION
CONTINUING MEDICAL EDUCATION (CME)
The Viral Hepatitis Congress is accredited by the European Accreditation Council for Continuing
Medical Education (EACCME) to provide the following CME activity for medical specialists. The
EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.
The Viral Hepatitis Congress is designated for a maximum of 13 hours of European external CME
credits. Each medical specialist should claim only those hours of credit that he/she actually spent
in the educational activity.
Through an agreement between the European Union of Medical Specialists and the American
Medical Association, physicians may convert EACCME credits to an equivalent number of AMA
PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit
can be found at www.ama-assn.org/go/internationalcme.
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for
ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by
the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of
Canada.
Participants wishing to count this meeting towards their CME profile must ensure that they sign
the register at the registration desk on a daily basis.
Participants requesting CME recognition are also required to complete and return a feedback
assessment form evaluating the value and learnings from specific sessions they attend. This will
be available from the registration desk and should be returned to this desk when leaving the
Congress or to the Organising Secretariat following the Congress.
EXHIBITION
Exhibition stands are located in the Level E1 Foyer. The hours of opening are as follows:
Thursday 9 October 2014
12.30–20.00
Friday 10 October 2014
10.00–18.20
Saturday 11 October 2014
10.00---15.30
Identification badges must be worn at all times to gain access to the exhibition area.
FIRST AID
First aid and medical care are available around the clock in the airport clinic, which is located in
Terminal 1, between Concourses B and C (Arrivals).
18
GENERAL INFORMATION
IDENTIFICATION AND SECURITY
Badges are proof of your registration to the Congress. Security staff will be in attendance
throughout the Congress and access will be denied to anyone not wearing their allocated
badge. If you lose your badge please return to the registration desk to obtain a replacement.
INTERNET AND WI-FI
Complimentary wireless Internet access is available to all participants wishing to use their own
laptops/mobile devices. Information on how to log on can be found in the ‘Joining Instructions’
provided at registration. For assistance please enquire at the registration desk.
An Internet access point – for participants who do not have their own laptops/mobile devices –
can also be found in the Level E1 Foyer, it will be open during exhibition opening hours.
Thursday 9 October 2014
12.30–20.00
Friday 10 October 2014
10.00–18.20
Saturday 11 October 2014
10.00---15.30
LIABILITY
In the event of cancellation, industrial disruption or other unforeseen circumstances, the
Congress organisers accept no responsibility for loss of monies incurred by participants.
OFFICIAL LANGUAGE
The official language of the Congress is English. There is no simultaneous interpretation.
19
GENERAL INFORMATION
ORGANISING SECRETARIAT
The Organising Secretariat will be available throughout the Congress, to contact them, please
visit the registration desk.
SCIENTIFIC COMMITTEE
The Scientific Committee may be contacted through the registration desk.
TELEPHONES
The nearest public telephones are located in the airport, which is reached via a covered walkway
from the hotel lobby.
Calling to and from Germany
The international country code for Germany is 49, and the area code for Frankfurt is 69.
National calls: 0 + city code + telephone number.
International calls: 00 + country code + city code + telephone number.
20
GENERAL INFORMATION
TRANSPORT
Arriving by plane
From Terminal 1: From the departure level in area A and C there is an escalator leading to the
covered footbridge, which is linked directly to the hotel.
From Terminal 2: Take the Skyline train, which travels between Terminal 1 and 2. From the
departure level in area A and C there is an escalator leading to the covered footbridge, which is
linked directly to the hotel.
Arriving by train
From the regional train station: Head toward the ICE station (AIRail Centre) from the regional
train station. On the bridge, which connects the airport to the ICE station, take a right toward
the hotel.
From the ICE station: Walk from the ICE station toward the airport. On the bridge, which
connects the airport to the ICE station, take a left toward the hotel.
Arriving by car
Motorways A3 and A5: At the Frankfurt junction (Frankfurter Kreuz) take the B43 toward
Frankfurt Airport, then head toward Terminal 2 (Arrival/Departures) and car park P3. The hotel
is signposted at the airport (small bed on a green traffic sign).
Taxis
Taxis are available at the adjoining airport, additionally, below are numbers of selected firms,
taken from the www.frankfurt-tourismus.de website (please note, these numbers are for
information only and do not represent a recommendation by the Organising Secretariat).
Taxi Frankfurt
+49 (0) 69/23 00 01
[email protected]
Time Car
+49 (0) 69/20 30 4
[email protected]
SGS Taxi
+49 (0) 69/79 30 79 99
[email protected]
Comet-Taxi GmbH
+49 (0) 69/70 76 69 – 0
[email protected]
21
WELCOME RECEPTION, LUNCHES AND REFRESHMENTS
LUNCH
Lunch will be available to all participants on Friday 10 and Saturday 11 October. Lunch will be
served in the Level E1 Foyer at the following times:
Friday 10 October 2014
13.20–14.20
Saturday 11 October 2014
12.25–13.25
If, at the time of registration, you indicated that you have a special dietary requirement, you
should speak to a member of the serving staff who will be able to provide you with your lunch.
REFRESHMENTS
Refreshments (tea, coffee, and mineral water) will be available during designated breaks, in the
Level E1 Foyer. Please refer to the Scientific Programme pages for specific timings.
WELCOME RECEPTION
The Welcome Reception will take place between 19.00 and 20.00 on Thursday 9 October in the
Level E1 Foyer, immediately following the end of the day’s programme.
All participants are invited to attend. Drinks and snacks will be served, giving participants the
opportunity to meet friends and colleagues in an informal setting, whilst viewing the poster
presentations and exhibition.
22
SCIENTIFIC PROGRAMME INFORMATION
POSTER INSTALLATION AND DISMANTLING
Scientific posters will be displayed in the foyer of the Sheraton Frankfurt Conference Center,
alongside the exhibition and catering areas.
Posters should be mounted between 10.00 and 12.30 on Thursday 9 October. Poster boards will
be provided for each accepted poster. Fixing materials and staff will be on hand to assist poster
presenters during this time.
Posters should be removed after 15.30 on Saturday 11 October (this is the time that the
exhibition area will close). Any posters not removed by 17.30 on Saturday 11 October will be
disposed of.
POSTER PRESENTATIONS
Authors are requested to complete the presenter availability card on their poster board
indicating at which refreshment and lunch breaks they will be available to discuss their poster.
Between 19.00 and 20.00 on Thursday 9 October, participants are invited to a reception around
the poster area. Presenters are asked to be by their posters at this time.
The Congress would like to thank Idenix Pharmaceuticals for their support in sponsoring the
poster area.
PRESENTATION PREVIEW
Plenary and Oral presenters must preview and upload their slides in the presentation preview
room on Level E1 of the Conference Center. Where possible, presenters are requested to
preview their materials the day before their allocated presentation time-slot, so that any
technical issues may be resolved. If this is not possible, presenters should preview their materials
at least 4 hours prior to their presentation.
PUBLICATION OF ABSTRACTS
The abstracts from this meeting have been published in a supplement to the Journal of Viral
Hepatitis. The supplement will be available online from the beginning of the Congress through
the website (www.viral-hep.org) and through the Congress app.
23
SCIENTIFIC PROGRAMME INFORMATION
SCIENTIFIC PROGRAMME AUDITORIA
All scientific sessions and industry symposia will take place on Level E1 in the main auditorium.
The pre-Congress Workshop will take place in the SkyLoft also located on Level E1.
WEB COVERAGE
The Congress website can be found at: www.viral-hep.org.
The abstracts from this meeting will be available as an online supplement to the Journal of Viral
Hepatitis, at: http://wileyonlinelibrary.com/journal/jvh.
Webcasts of the plenary presentations and copies of posters (subject to speaker agreement) will
be available at www.viral-hep.org shortly after the meeting.
24
VENUE MAP
25
CHAIRS’ BIOGRAPHIES
IRA M JACOBSON
Chief, Division of Gastroenterology and Hepatology and
Vincent Astor Professor of Medicine, Weill Cornell Medical College,
New York, USA
Ira M Jacobson is Chief of the Division of Gastroenterology and Hepatology and Vincent Astor
Professor of Medicine, Weill Cornell Medical College, New York, USA, and Attending Physician
at New York Presbyterian Hospital. He is also Medical Director of the Center for the Study of
Hepatitis C at Weill Cornell and Rockefeller University. Dr Jacobson received his Bachelor of
Science from Yale University, Connecticut, and his MD from Columbia University College of
Physicians and Surgeons, New York. He has been an investigator in many trials of hepatitis C
therapy for 25 years. He was principal investigator of the WIN-R trial, a large US multicenter
study focusing on ribavirin dosing, the ADVANCE trial of telaprevir, the QUEST-1 study on
simeprevir, the StartVerso 3 study on faldaprevir, and the POSITRON study on sofosbuvir. Dr
Jacobson is a Fellow of the American College of Physicians, the American Gastroenterological
Association (AGA), the American College of Gastroenterology (ACG), and the American
Association for the Study of Liver Diseases (AASLD), and a member of the American Society for
Gastrointestinal Endoscopy, and the European Association for the Study of the Liver (EASL). He is
the author of more than
200 articles, chapters, and abstracts, appearing in the New England Journal of Medicine,
Hepatology, and Clinical Gastroenterology and Hepatology, among others, and has served as an
Associate Editor of the Journal of Hepatology. Dr Jacobson has edited two books, ERCP:
Diagnostic and Therapeutic Applications and ERCP and Its Applications, as well as a volume on
hepatitis B for Clinics in Liver Disease.
26
CHAIRS’ BIOGRAPHIES
STEFAN ZEUZEM
Professor of Medicine, J.W. Goethe-University Hospital, Frankfurt am
Main, Germany
Stefan Zeuzem is Professor of Medicine and Chief of the Department of Medicine I at the J.W.
Goethe-University Hospital, Frankfurt am Main, Germany. He received medical training at
medical schools in Frankfurt am Main, Newcastle-upon-Tyne, UK and Cambridge, UK. Professor
Zeuzem subsequently completed postdoctoral fellowships in endocrinology and
gastroenterology, as well as research sabbaticals at Frankfurt am Main, Newcastle-upon-Tyne,
and Yale, Connecticut, USA. From 2002 to 2006 he was Full Professor of Medicine and Chairman
of the Department of Internal Medicine II at Saarland University Hospital, Homburg/Saar,
Germany. His clinical areas of expertise include gastroenterology, hepatology, liver
transplantation, endoscopy, gastrointestinal oncology and endocrinology. His current research
interests are cellular physiology, molecular biology of hepatitis viruses, viral kinetics, the role of
hepatitis C in hepatocarcinogenesis, and the stratification and optimisation of antiviral
treatment. Professor Zeuzem is a member of numerous professional associations and has been
recognised with many honours and awards for his outstanding research accomplishments. He is
the co-author of book chapters on many aspects of internal medicine and is the author or
co-author of numerous articles, which have been published in top journals including The Lancet
and the New England Journal of Medicine.
27
SCIENTIFIC COMMITTEE BIOGRAPHIES
NEZAM AFDHAL
Professor of Medicine, Harvard Medical School, Boston, USA
Nezam Afdhal is Professor of Medicine at Harvard Medical School, Boston, USA. Professor Afdhal
obtained his medical degree from the Royal College of Surgeons, Dublin, Ireland. After
completing a residency in medicine, he went on to complete his fellowship in gastroenterology
at St Vincent’s Hospital, University College Dublin and a second fellowship in hepatology at
Boston University. Professor Afdhal’s research interests include liver fibrosis, liver injury from
hepatitis viruses, management of end-stage liver disease and treatment of viral hepatitis. As well
as serving on editorial boards and acting as a reviewer, Professor Afdhal has been an author on
numerous peer-reviewed publications, in journals such as the New England Journal of Medicine,
Hepatology, Journal of Hepatology, Gastroenterology and The Lancet. He is also a member of
AGA, AASLD and EASL.
28
SCIENTIFIC COMMITTEE BIOGRAPHIES
ANTONIO CRAXÌ
Full Professor of Gastroenterology and Internal Medicine, University
of Palermo, Palermo, Italy
Antonio Craxì is Full Professor of Gastroenterology and Internal Medicine at the University of
Palermo, Palermo, Italy, where he is also Director of Gastroenterology and Hepatology at the
University’s Academic Department of Internal Medicine. He obtained his medical degree from
the University of Palermo and trained in gastroenterology at the University of Rome. Following
this, he was a Research Fellow at the Royal Free Hospital, London, UK. Professor Craxì’s main
research interests range from pathobiology of hepatitis B and C to antiviral therapy,
nonalcoholic steatohepatitis, hepatocellular carcinoma and the natural history and
epidemiology of chronic liver disease. He is a member of AASLD, EASL, the Italian Association for
the Study of the Liver (AISF) and the International Liver Cancer Association (ILCA). Among his
contributions to the hepatology arena are more than 250 full papers published in international
journals, and presentations at both national and international meetings. He serves, or has
served, on the editorial boards for several leading journals, including Hepatology, Journal of
Hepatology, Current Opinions in Hepatology, World Journal of Gastroenterology, Viral Hepatitis
Reviews and Hepatology Reviews.
29
SCIENTIFIC COMMITTEE BIOGRAPHIES
GEOFFREY DUSHEIKO
Professor of Medicine, Royal Free Hospital and University College
School of Medicine, London, UK
Geoffrey Dusheiko is Professor of Medicine at the Royal Free Hospital and University College
School of Medicine, London, UK. He earned his Bachelor of Medicine, Bachelor of Surgery
degree from the University of Witwatersrand in Johannesburg, South Africa. After graduating,
he completed his internship at Baragwanath Hospital in Johannesburg and his residency at
Johannesburg Hospital. His fellowships were conducted at the Johannesburg Hospital Liver Unit
and the National Institutes of Health (NIH) in Maryland and the University of Minnesota, USA.
Professor Dusheiko’s research interests include the management and treatment of hepatitis B
and C and small hepatocellular carcinoma; he has a special interest in research in viral hepatitis,
focusing on viral genotyping, applied molecular virology, the natural history of chronic viral
hepatitis, and antiviral therapies. He has served on several editorial boards including the Journal
of Viral Hepatitis, Hepatology, Best Practice and Research: Clinical Gastroenterology, and GUT
and is the author of more than 330 published articles. He is currently a Co-Editor of Alimentary
Pharmacology and Therapeutics. A member of several organisations, including the International
Association for the Study of the Liver (IASL), AASLD and EASL, he is a Fellow of the Royal College
of Physicians, the Royal College of Physicians of South Africa, and the Royal College of Physicians
of Edinburgh. Professor Dusheiko has served as Educational Councillor on the Governing Board
of EASL for the past 4 years. He is a Director of the Skipton Fund and is a guidelines writer for
the World Health Organization (WHO).
30
SCIENTIFIC COMMITTEE BIOGRAPHIES
JORDAN FELD
Assistant Professor of Medicine, University of Toronto, Ontario,
Canada
Jordan Feld completed his clinical training in internal medicine and gastroenterology at the
University of Toronto, Ontario, Canada, followed by a postdoctoral fellowship in the Liver
Diseases Branch of the NIH, Bethesda, Maryland, USA. He also received a Masters of Public
Health degree from Johns Hopkins University, Baltimore, Maryland. Dr Feld is on the faculty at
the University of Toronto as a clinician-scientist at the Toronto Centre for Liver Disease and the
Sandra Rotman Centre for Global Health. His laboratory work focuses on understanding the
innate antiviral immune response in viral hepatitis infections and he leads a clinical research
programme with a focus on international health.
31
SCIENTIFIC COMMITTEE BIOGRAPHIES
GRAHAM R FOSTER
Professor of Hepatology, Queen Mary, University of London, London,
UK
Graham R Foster is Professor of Hepatology at Queen Mary, University of London, London, UK,
and a Consultant at Barts and The London NHS Trust, East London. He trained in medicine at
universities in Oxford and London in the 1980s and completed a PhD in Molecular Biology in
1992. Professor Foster has a long-standing interest in the management of chronic viral hepatitis
and runs a clinical research programme studying its natural history, its impact upon patients and
their communities and novel therapies for this disease. He supervises a laboratory research
programme investigating the mode of action of the different type I interferons and novel
replication models for hepatitis C. He is Past-President of the British Association for the Study of
the Liver (BASL), Vice-Chairman for the UK Department of Health Advisory Group on Hepatitis
and a member of a number of patient advocacy groups. He is the Editor of the Journal of Viral
Hepatitis and has published widely in the field of viral liver disease.
32
SCIENTIFIC COMMITTEE BIOGRAPHIES
PATRICK MARCELLIN
Professor of Hepatology, University of Paris, Paris, France
Patrick Marcellin is Professor of Hepatology at the University of Paris and Head of the Viral
Hepatitis Research Unit in Hôpital Beaujon, Clichy. He earned his medical degree from the
University of Paris and undertook postgraduate training in both internal medicine and
gastroenterology-hepatology at the Assistance Publique-Hôpitaux de Paris. Professor Marcellin
completed research fellowships in immunology (College of Physicians and Surgeons at Columbia
University, New York City, USA) and virology (Institut Pasteur, Paris). He also holds a PhD in
virology. Since 1984, he has been actively involved in laboratory and clinical research on viral
hepatitis and liver diseases. His major focus has been on viral hepatitis therapy, and as such he
has been the principal investigator on initial trials of first interferons and antivirals and on
several pivotal studies investigating therapies for chronic hepatitis B and C. Professor Marcellin
was a member of the Scientific Committee of EASL and organised the EASL Consensus
Conference on Hepatitis C in 1999 and the EASL Consensus Conference on Hepatitis B in 2002.
He was the Chairman of the panel on the 2009 EASL hepatitis B guidelines. He is the President of
APHC that has organised the Annual Paris Hepatitis Conference for the last 10 years.
33
SCIENTIFIC COMMITTEE BIOGRAPHIES
HENDRIK REESINK
Associate Professor, Department of Gastroenterology and
Hepatology, Academic Medical Centre, University of Amsterdam,
Amsterdam, The Netherlands
Hendrik Reesink is Associate Professor in the Department of Gastroenterology and Hepatology
of the Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. After
receiving his medical degree from the Faculty of Medicine at the University of Amsterdam, he
specialised in immunohaematology and transfusion medicine at the Central Laboratory of The
Netherlands Blood Transfusion Service, Amsterdam. Hendrik Reesink received his training in
internal medicine and his PhD from the Wilhelmina Gasthuis, University of Amsterdam.
Throughout the last 10 years, Hendrik Reesink’s research interest has mainly been in the early
development and evaluation of new medicines for the treatment and cure of chronic hepatitis B
and C patients. He is a member of numerous research groups and national and international
advisory boards. He is co-author of numerous publications that have appeared in the New
England Journal of Medicine, The Lancet, Gastroenterology and Hepatology.
34
SCIENTIFIC COMMITTEE BIOGRAPHIES
JÜRGEN ROCKSTROH
Professor of Medicine, University of Bonn, Bonn, Germany
Jürgen Rockstroh is Professor of Medicine and Head of the HIV Outpatient Clinic at the
University of Bonn, Bonn, Germany. He earned his medical degree and completed his residency
at the Rheinische Friedrich-Wilhelms University of Bonn. His department treats the world’s
largest cohort of HIV-infected haemophiliacs. Professor Rockstroh is also involved in HIV research
on antiretroviral therapy, the course of HIV disease in patients with haemophilia and HIV and
hepatitis co-infection. He has been an investigator in multiple clinical trials of antiretroviral
agents and treatments for HIV and hepatitis co-infection. An active member of the HIV/AIDS
treatment community, Professor Rockstroh was Chairman of the German Clinical AIDS Working
Group (KAAD) from 1998 to 2007 and President of the German AIDS Society (DAIG) from 2007 to
2011. He chaired the Organising Committee for the First and Second International Workshops
on HIV and Hepatitis Co-infection in Amsterdam, and was on the International Organising
Committee for the first European Consensus Conference on the Treatment of Chronic Hepatitis
B and C in HIV Co-infected Patients in 2005. The German Society for Infectious Diseases awarded
Professor Rockstroh and his co-authors the prize in clinical infectious diseases in 2002, and the
national AIDS research prize in 2005. Professor Rockstroh is the author or co-author of more
than 350 publications in peer-reviewed journals, and more than 30 book chapters.
35
SCIENTIFIC COMMITTEE BIOGRAPHIES
HEINER WEDEMEYER
Associate Professor, Department of Gastroenterology, Hepatology
and Endocrinology, Hanover Medical School, Hanover, Germany
Heiner Wedemeyer is Managing Senior Physician and Associate Professor in the Department of
Gastroenterology, Hepatology and Endocrinology at Hanover Medical School, Hanover,
Germany. Here he coordinates the Hepatitis Diagnostic Laboratory and, together with PD Dr
Markus Cornberg, he is leading a research group on cellular immunology in viral hepatitis.
Professor Wedemeyer studied musicology and medicine and graduated in medicine from the
University of Göttingen. He started training in internal medicine at Hanover Medical School.
From 1998 to 2000 he spent 2.5 years as a research fellow in immunology in the Liver Diseases
Section at the NIH in Bethesda, Maryland, USA, in the group of Barbara Rehermann. In 2001, he
returned to Hannover and completed his specialist training in gastroenterology and hepatology.
He is Fellow of the European Board of Gastroenterology and Hepatology. Since 2002 Professor
Wedemeyer has been involved in the scientific coordination of the German Network of
Competence on Viral Hepatitis (Hep-Net) and the German Liver Foundation (since 2006).
In 2008, he was elected as member of the Scientific Committee of EASL and was Secretary
General from 2009 to 2011. Currently, he is representing EASL on the UEG Scientific Committee.
He has had various coordinating responsibilities in the establishment of several national and
international guidelines on the management of hepatitis B and C and hepatocellular carcinoma.
Professor Wedemeyer has worked on basic and clinical aspects of hepatitis virus infections since
1996. His main interests are the immunopathogenesis of hepatitis B, C, D and E and the
development of novel immunomodulatory therapies such as therapeutic vaccines in hepatitis C.
He has been principal investigator in several Phase I–IV clinical trials on antivirals and
immunotherapies in viral hepatitis, has published more than 300 articles in peer-reviewed
journals and is the editor of four books. The current Hirsch-Index of Professor Wedemeyer is
47 and his publications have been cited more than 10,000 times. He has been awarded the
Hans Popper Award of IASL (2002), the ‘Präventionspreis der Deutschen Gesellschaft für Innere
Medizin’ (2008), the Innovation Award of the German Medical Faculties (2011) and the
Rudolph-Schoen-Award (2011). The research of Heiner Wedemeyer has been funded by the
Deutsche Forschungsgemeinschaft, the German Ministry for Research and Education (BMBF), the
European Union, EASL, Hep-Net, the Robert-Koch-Institute and the Bill and Melinda Gates
Foundation.
36
SPEAKER BIOGRAPHIES
HARVEY J ALTER
Distinguished NIH Investigator, Department of Transfusion Medicine,
NIH, Maryland, USA
Harvey J Alter has spent most of his research career at the NIH. He is currently designated
Distinguished NIH Investigator and serves as Chief of Clinical Studies and Associate Director for
Research in the Department of Transfusion Medicine. Dr Alter was co-discoverer of the Australia
antigen that later proved to be the hepatitis B virus and was principal investigator in studies
that identified non-A, non-B hepatitis, defined its chronic sequela and later showed its link to
the hepatitis C virus. His prospective studies of transfusion-associated hepatitis demonstrated
how different donor interventions reduced hepatitis incidence from 30% in 1970 to near zero in
1997. For these studies, Dr Alter has been awarded the Landsteiner Prize from the American
Association of Blood Banks, the Presidential Award of the International Society of Blood
Transfusion, the Inserm Medal from France, and was elected to fellowship in the American
Association of Physicians. For his contributions to the discovery of the non-A, non-B/hepatitis C
virus and for his vital role in reducing hepatitis risk and improving the safety of the blood
supply, Dr Alter was the co-recipient of the year 2000 Clinical Lasker Award, was elected to the
National Academy of Sciences and the Institute of Medicine and was made a Master of the
American College of Physicians. In 2011, he became the first haematologist to receive the
Distinguished Achievement Award of the American Association for the Study of Liver Diseases.
37
SPEAKER BIOGRAPHIES
MARINA BERENGUER
Professor of Medicine, Department of Digestive Diseases, Hepatology
and Liver Transplantation Unit, La Fe University Hospital and
CIBERehd, Valencia, Spain
Marina Berenguer is a Consultant Hepatologist at La Fe University Hospital, Valencia, Spain. She
trained in medicine at the University of Valencia before completing a fellowship at the VA
Medical Center/University of California, USA with Dr T Wright. She was recently appointed Full
Professor of Medicine at the University of Valencia, Faculty of Medicine. Professor Berenguer is
well recognised for her important contributions in the field of post-transplantation HCV liver
disease. She was involved in the creation of various consensus documents on viral hepatitis and
liver disease, and she is an active committee member for several national and international
hepatology and liver transplantation societies. She has received numerous grants for her
research in antiviral therapy for hepatitis C and awards for her medical research. Since its
creation in 2006, she has also coordinated research within a national research network in
hepato-gastroenterology (‘Centro de Investigación Biomédica en Red En Enfermedades
Hepáticas y Digestivas’, CIBER-ehd). Professor Berenguer serves as Associate Editor for the
Journal of Hepatology and Liver Transplantation and is responsible for the Liver Transplantation
section within the Journal of Hepatology. She is the author of more than 150 publications in
peer-reviewed journals as well as over 50 chapters in international and national textbooks.
38
SPEAKER BIOGRAPHIES
MARC BOURLIÈRE
Head of the Hepato-Gastroenterology Department, Hospital Saint
Joseph, Marseilles, France
Marc Bourlière received his medical degree in 1987 from Marseilles University, Marseilles, France.
He completed his fellowship training at Marseilles University Hospital and at Beaujon University
Hospital, Paris. He was an Assistant in Hepatology at the Conception University Hospital,
Marseilles before taking up his current position as Head of the Hepato-Gastroenterology
Department at Hospital Saint Joseph, Marseilles. Dr Bourlière and his group have participated in
hepatitis B and C and HCC clinical trials; his current research focus is the use and development of
noninvasive biomarkers in hepatitis and the development of new antiviral therapy for hepatitis
C. Dr Bourlière has published more than 190 papers or chapters in international journals and
books focused on hepatitis B and C. As well as reviewing for many specialist journals, he has
served as a member of the Editorial Boards of Gastroenterologie and Clinique et Biologique.
Dr Bourlière belongs to the French Agency for AIDS and hepatitis research (ANRS) and he heads
the ANRS group that coordinates hepatitis clinical therapeutic trials (AC24). He is also a member
of several professional societies including EASL and the French Association for the Study of the
Liver (AFEF).
39
SPEAKER BIOGRAPHIES
DAVID BURGER
Professor of Clinical Pharmacy, Radboud University, Nijmegen,
The Netherlands
David Burger received his pharmacy degree from Utrecht University, Utrecht, The Netherlands in
1990. He completed his PhD thesis, entitled ‘Bio-analysis and clinical pharmacokinetics of
antiretroviral agents in HIV-infected individuals’ at the Slotervaart Hospital, Amsterdam, in 1994.
After this, he moved to the Radboud University Nijmegen Medical Centre for his hospital
pharmacist training. From 1997 to 2005, he worked as a hospital pharmacist responsible for
coordination of clinical trials conducted at the Radboud University Nijmegen Medical Centre.
Since 1997 he has been leading a research group focusing on clinical pharmacology of
antimicrobial agents with emphasis on HIV, TB, fungal infections, and HCV. He is a member of
the Editorial Board of the www.hiv-druginteractions.org and www.hep-druginteractions.org
websites on behalf of the European AIDS Clinical Society. He is a member of the Organising
Committee of the Annual International Workshop on Clinical Pharmacology of HIV/Hepatitis
Therapy. Since April 2011 he has been appointed as a Professor of Clinical Pharmacy at the
Radboud University Nijmegen. He is co-author of more than 300 publications in this field. His
topics of interest are drug–drug interactions, paediatric pharmacology, therapeutic drug
monitoring, and operational research in resource-limited countries.
40
SPEAKER BIOGRAPHIES
MARIA BUTÍ
Head of the Liver Unit, Department of Internal Medicine, Vall
d’Hebron University Hospital, Barcelona, Spain
Maria Butí is Head of the Liver Unit, Department of Internal Medicine, at the Vall d’Hebron
University Hospital, Barcelona, Spain and currently Professor of Medicine and Chief of Internal
Medicine and Hepatology at the Hospital General Universitari Valle Hebron, Barcelona. She
earned her medical degree at the University of Barcelona and her PhD in internal medicine at
the University ‘Autónoma’ de Barcelona, Spain. Dr Butí has worked in viral hepatitis for the last
15 years, particularly in diagnosis and therapy of hepatitis B and C. She has been widely
published in the field of liver disease, with numerous papers and contributions to books. Dr Butí
was the Secretary of the Spanish Association for the Study of Liver Diseases, and is an active
member of EASL, AASLD and various professional societies.
41
SPEAKER BIOGRAPHIES
MASSIMO COLOMBO
Professor of Gastroenterology, University of Milan, Milan, Italy
Massimo Colombo is Professor of Gastroenterology at the University of Milan, Milan, Italy. His
research interests include diagnosis and treatment of viral hepatitis and liver cancer. He is
Chairman of the Departments of Liver, Kidney, Lung and Bone Marrow Units and Organ
Transplant and of the Division of Gastroenterology and Hepatology at the Policlinic University
Hospital, Milan. Professor Colombo received his medical degree in medicine from the University
of Milan where he completed a residency in gastroenterology at Policlinic Maggiore Hospital. He
completed his fellowship in liver disease at the Mount Sinai Hospital, New York, USA. Professor
Colombo has been the Editor-in-Chief of the Journal of Hepatology from 2005 to 2009. He is
affiliated with several professional associations and societies, including the American Association
for the Study of Liver Diseases, European Association for the Study of the Liver and other
professional bodies in Italy. He is an international lecturer and speaker, is on the editorial board
of many hepatology journals globally, and has published more than 380 original manuscripts in
peer-reviewed journals; with 15,887 citations and a H-index 52. In 2010 he received the EASL
Recognition Award for outstanding medical and scientific contribution. In 2014 he received the
Thannhauser Medal Award from the German Gastroenterology Society for clinical and scientific
contributions in the field of liver disease.
42
SPEAKER BIOGRAPHIES
FRANCESCO DAMMACCO
Professor of Internal Medicine, Department of Internal Medicine and
Clinical Oncology, University of Bari Medical School, Bari, Italy
Francesco Dammacco is a Full Professor of Internal Medicine at the Department of Internal
Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy, and Director of the
Graduate School of Oncology at the same university. He has held a number of academic
positions, including Visiting Scientist for 1 year at the University of Copenhagen Medical School,
Denmark; Visiting Scientist for 1 year at the University of Malmö Medical School, Sweden; and
Fellow and Visiting Scientist for 18 months at the New York University School of Medicine, USA.
He has served as sub-project coordinator for three, 5-year finalised projects of the Italian
Research Council (15 years in total) and is a member of several international societies of internal
medicine and immunology. In addition, he was President of the Italian Society of Internal
Medicine and of the College of Italian Professors of Internal Medicine. He is Editor-in-Chief of
the quarterly medical journal Clinical and Experimental Medicine, published by Springer Verlag
and has published a two-volume immunology handbook in Italian, Immunologia in Medicina.
His scientific interests include acute and chronic liver diseases, with special emphasis on HCVrelated cryoglobulinemic vasculitis, immunoproliferative disorders such as multiple myeloma and
malignant lymphomas, connective tissue disorders, and immunodeficiency diseases. In these
fields of research he is author or co-author of a total of 463 papers published in peer-reviewed
journals (PubMed, June 2014).
43
SPEAKER BIOGRAPHIES
MICHAEL FRIED
Professor of Medicine, Director, UNC Liver Center, University of North
Carolina, North Carolina, USA
Michael Fried is Professor of Medicine and Director of the UNC Liver Center at the University of
North Carolina, North Carolina, USA. Professor Fried received his medical degree from Tel Aviv
University, Tel Aviv, Israel, in 1984 and completed his residency in internal medicine and
fellowship in gastroenterology at the SUNY Health Science Center, New York. Professor Fried
has performed clinical and laboratory studies of viral hepatitis since 1990, when he served for
3 years as a fellow at the Liver Diseases Section, NIH, Maryland. He has served as principal
investigator on numerous clinical trials of various antiviral agents for chronic hepatitis B and
hepatitis C. Professor Fried has had continuous NIH extramural funding for more than 10 years
as principal investigator on several NIH cooperative clinical trials. He is also a recipient of an NIH
career development award (K24), which allows him to provide mentorship to junior
investigators in hepatitis research. He is the primary author or co-author of more than
140 manuscripts, reviews, and book chapters in the field of viral hepatitis. Professor Fried was
recently elected to the Governing Board of the AASLD.
44
SPEAKER BIOGRAPHIES
HARRY JANSSEN
Head of Hepatology, University Health Network, Toronto Western
and Toronto General Hospital, Toronto, Canada
Harry Janssen is Professor of Medicine, Francis Family Chair in Hepatology and Head of
Hepatology at Toronto Western and Toronto General Hospital, University Health Network,
Toronto, Canada. He graduated from medical school at the Radboud University of Nijmegen,
The Netherlands. During his studies he spent 1 year as research fellow in Hepatology at the
Mayo Clinic, USA. He obtained his PhD in Rotterdam on the role of immune modulating therapy
in chronic hepatitis B and then trained in internal medicine at Leiden University Medical Center
and in Gastroenterology and Hepatology at Rotterdam Erasmus University Medical Center.
Following his registration as a Gastroenterologist he returned to the Mayo Clinic for a research
fellowship in hepatology at the Center of Basic Research in Digestive Diseases. In 2001 he
became a staff member and in 2006 he was appointed as Full Professor of Hepatology and Chief
of the Section of Liver Diseases and Transplantation in Rotterdam. In early 2013 he was
appointed as Head of Hepatology at the Toronto Center for Liver Disease. As principal
investigator, Professor Janssen coordinated numerous European and global multicentre studies
on antiviral treatment for chronic viral hepatitis. He was awarded a Clinical Fellowship and an
Innovational Research grant from The Netherlands Organisation of Scientific Research, to study
strategies of immune control in viral hepatitis and published many international articles on this
subject. Professor Janssen has been Chairman of the Dutch Association of Hepatology and was
elected as Rising Star in Gastroenterology and Hepatology by the Association of the National
European Societies of Gastroenterology. He has been a member of the Editorial Board of
Hepatology, Journal of Hepatology, Journal of Viral Hepatitis and Best Practice in
Gastroenterology. He has published more than 300 original peer-reviewed papers. In addition to
his longstanding expertise in antiviral therapy of chronic viral hepatitis, Professor Janssen is a
leading scientist in the field of vascular disorders of the liver.
45
SPEAKER BIOGRAPHIES
KRIS V KOWDLEY
Director of the Liver Center of Excellence and Director of Research,
Digestive Disease Institute, Virginia Mason Medical Center, and
Clinical Professor of Medicine, University of Washington, USA
Kris V Kowdley is Director of the Liver Care Network at Swedish Medical Center, a Clinical
Professor of Medicine at the University of Washington, and an Affiliate Investigator at Benaroya
Research Institute at Virginia Mason, all located in Seattle, Washington, USA. Dr Kowdley
received his BS in Biology and Anthropology as a member of the Dean's List at Columbia
University, and his medical degree from Mount Sinai School of Medicine, New York. He
completed his internship and residency at Oregon Health Science University and his fellowship in
gastroenterology and hepatology at Tufts University School of Medicine, Boston. Dr Kowdley
has presented his research in liver diseases at more than 130 national and international medical
centres and scientific symposia. He is the author of more than 370 articles, book chapters,
reviews and commentaries in this area and has been published in the Annals of Internal
Medicine, Archives of Surgery, Gastroenterology, Hepatology, American Journal of Physiology,
New England Journal of Medicine, and other professional publications.
46
SPEAKER BIOGRAPHIES
PAUL MARTIN
Professor of Medicine, University of Miami, Miami, USA
Paul Martin is Professor of Medicine and Chief of the Division of Hepatology at the University of
Miami, Miami, USA. He is a native of Dublin, Ireland, where he graduated from medical school
at University College, Dublin, and then specialised in internal medicine, training initially in
Dublin and then at the University of Alberta, Canada. He undertook training in
gastroenterology at Queen’s University, Ontario, and subsequently was a Medical Staff Fellow at
the Liver Unit, NIH, Maryland, USA. Professor Martin is a member of numerous professional
societies, including the AST and AASLD, and serves on the American Board of Internal Medicine.
He is a Councillor-at-Large for AST and a Fellow of the Royal College of Physicians of Ireland and
of the London College of Physicians, UK. He has been involved in numerous clinical trials in
hepatitis B and C, and has published more than 200 peer-reviewed papers. He has also
contributed to editorials, reviews and book chapters, as well as editing several books.
47
SPEAKER BIOGRAPHIES
DARIUS MORADPOUR
Professor of Medicine, University of Lausanne and Chief, Division of
Gastroenterology and Hepatology, University Hospital of Lausanne
(CHUV), Lausanne, Switzerland
Darius Moradpour received his medical degree from the University of Zurich, Switzerland and
completed his training in internal medicine at the University Hospital in Zurich. After a 3-year
postdoctoral fellowship at the Massachusetts General Hospital, Harvard Medical School, Boston,
USA, he joined the University Hospital in Freiburg im Breisgau, Germany to complete his clinical
training in gastroenterology and hepatology and to establish a research group focused on the
molecular virology and pathogenesis of hepatitis C. At the University of Freiburg he became
Assistant Professor in 1999 and Associate Professor in 2004. In 2002–2003 he was a Visiting
Professor at the Center for the Study of Hepatitis C, The Rockefeller University, New York, USA.
In 2004, he joined the University Hospital of Lausanne (CHUV), Switzerland as Chief of
Hepatology. Since 2006 he has been Full Professor and since 2009 has directed the Division of
Gastroenterology and Hepatology of the CHUV. Current research interests include the structure
and function of the HCV replication complex, virus-host interactions in hepatitis C, the molecular
virology of hepatitis E as well as translational and clinical studies in viral hepatitis, hepatocellular
carcinoma and other liver diseases. He has published more than 250 original articles, reviews and
book chapters. He is the President of the Swiss Association for the Study of the Liver and an
Associate Editor of the Journal of Hepatology and has served as Associate Editor of Hepatology,
Chairman of the Scientific Committee of the Swiss Hepatitis C Cohort Study, and member of the
Governing Board of EASL as well as the Editorial Board of the Journal of Virology. He received
the Prix Leenaards in 2006, the Prix Cloëtta in 2008, the Prize of Honor of the Swiss Society of
Gastroenterology in 2009, and the title of Doctor Honoris Causa of the University of Lyon,
France in 2012.
48
SPEAKER BIOGRAPHIES
FRANCESCO NEGRO
Professor of Specialty Medicine and of Pathology and Immunology,
University of Geneva, Geneva, Switzerland
Francesco Negro is Professor at the Departments of Specialty Medicine and of Pathology and
Immunology of the University of Geneva, Geneva, Switzerland. He is also Founder and Chairman
of the Swiss Hepatitis C Cohort Study. Professor Negro earned his medical degree in 1982 and
was board-certified in gastroenterology in 1986 at the University of Torino, Italy. He undertook
postdoctoral training at the Division of Molecular Virology and Immunology, Georgetown
University, USA, and at the Hepatitis Section, National Institute of Allergy and Infectious
Diseases, NIH, Maryland, between 1986 and 1989. Professor Negro analysed hepatitis C virus
replication at the tissue level using several distinct approaches, establishing anatomo-clinical
correlations. His studies led him to associate hepatitis C genotype 3a with a particular form of
severe liver steatosis, and to analyse the mechanisms thereof. More recently, Professor Negro’s
work has focused on the pathogenesis of extrahepatic manifestations associated with hepatitis
C, and particularly, on the mechanisms leading to glucose metabolism alterations, such as insulin
resistance and diabetes. He has participated in several clinical trials in acute and chronic
hepatitis C and is the author or co-author of more than 200 peer-reviewed manuscripts in the
field of hepatology.
49
SPEAKER BIOGRAPHIES
DAVID NELSON
Professor of Medicine and Assistant Vice-President for Research,
Director, Clinical and Translational Science Institute, University of
Florida, Gainsville, USA
David Nelson is Professor of Medicine and Assistant Vice-President for Research at the University
of Florida, Gainsville, USA, where he serves as the Director of the Clinical and Translational
Science Institute. The mission of this NIH-funded institute is to improve how biomedical research
is conducted and to enable scientists to work together to accelerate the translation of
laboratory discoveries into clinical treatments. He received his undergraduate degree from
Dartmouth College, his medical degree from SUNY Upstate University in Syracuse, completed a
residency in internal medicine at the University of Massachusetts, and obtained fellowship
training in gastroenterology and hepatology at the University of Florida. Dr Nelson’s area of
clinical expertise is hepatology with an emphasis on the management of viral hepatitis and liver
cancer. Dr Nelson also has strong translational research interests, focusing primarily on the
immunopathogenesis and treatment of chronic hepatitis C and hepatocellular carcinoma. In
2013, he was recognised as one of the Clinical Research Forum’s Top 10 Clinical Research
Achievers. He currently oversees more than 15 active clinical trials and has a 15-year track record
of NIH funding. He serves as principal investigator on both basic science and clinical research
grants, along with mentoring/training grants in gastroenterology and hepatobiliary diseases.
Dr Nelson has an impressive record of academic achievement with more than $30 million in
research funding and more than 200 publications to his name.
50
SPEAKER BIOGRAPHIES
CHRISTOPH SARRAZIN
Associate Director and Professor of Medicine, J.W. Goethe-University
Hospital, Frankfurt am Main, Germany
Christoph Sarrazin is Professor of Medicine at J.W. Goethe-University Hospital, Frankfurt am
Main, Germany. He trained at medical schools in Bonn and Würzburg, and graduated in 1994.
He served as a postdoctoral fellow specialising in internal medicine, gastroenterology and
hepatology at J.W. Goethe-University Hospital from 1994 to 2002. Professor Sarrazin took over
his current position as Professor of Medicine in 2009. He has been funded by the Deutsche
Forschungsgemeinschaft, the Federal Ministry of Education and Research for the European
Union and Hep-Net. For more than 10 years, Professor Sarrazin has worked on basic and clinical
aspects of hepatitis virus infections. His main research interests are viral determinants of
resistance to the treatment of viral hepatitis with interferon, ribavirin and direct antiviral drugs.
He participated in numerous national and international Phase I–III studies in chronic viral
hepatitis. Professor Sarrazin has published more than 250 publications on basic research and
clinical aspects of chronic liver diseases, as well as evaluation of hepatitis B and C molecular
assays.
51
SPEAKER BIOGRAPHIES
ROBERT SCHOOLEY
Head of the Division of Infectious Diseases, Vice-Chair of the
Department of Medicine and Co-Director of the UCSD Center for
AIDS Research, University of California, San Diego, USA
Robert Schooley is a graduate of the Johns Hopkins University School of Medicine, Baltimore,
USA. He completed an internal medicine residency at the Johns Hopkins Hospital and infectious
disease fellowships at the National Institute of Allergy and Infectious Diseases and the
Massachusetts General Hospital. He joined the faculty of Harvard Medical School in 1981 and
was recruited to the University of Colorado in 1990 where he served as Head of the Division of
Infectious Diseases. In 2005 he joined the faculty at the University of California, San Diego where
he currently serves as Head of the Division of Infectious Diseases, Vice-Chair of the Department
of Medicine and Co-Director of the UCSD Center for AIDS Research. He serves as a member of
the AASLD/IDSA HCV Treatment Guidelines Panel and was a member of the US Department of
State’s Scientific Advisory Committee for the PEPFAR Program. His research interests are in the
diagnosis, pathogenesis and therapy of viral infections and in global health.
52
SPEAKER BIOGRAPHIES
UWE SIEBERT
Professor of Public Health, Chair, Department of Public Health and
Health Technology Assessment, University for Health Sciences,
Medical Informatics and Technology, Hall in Tirol, Austria
Uwe Siebert is Professor of Public Health, Chair of the Department of Public Health and Health
Technology Assessment at the University for Health Sciences, Medical Informatics and
Technology (UMIT), Hall in Tirol, Austria, and the Director of the Division for HTA in the
ONCOTYROL – Center for Personalized Cancer Medicine in Austria. He is also Adjunct Professor
of Health Policy and Management at the Harvard School of Public Health and Director of the
Program on Cardiovascular Research at the Institute for Technology Assessment and Department
of Radiology at the Massachusetts General Hospital, Harvard Medical School, Boston, USA. After
medical school, Professor Siebert worked as a physician in international public health projects.
He then earned an MPH (University of Munich, Germany), MSc in Epidemiology (Harvard
University), and ScD in Health Policy and Management (Harvard University), and he was the
Director of the Bavarian Public Health Research & Coordinating Center at the University of
Munich. His research interests include applying evidence-based quantitative and translational
methods from public health, epidemiology, comparative effectiveness research, outcomes
research, economic evaluation and decision sciences in the framework of health technology
assessments (HTA) as well as in the clinical context of routine healthcare. His current substantive
research focuses on hepatitis C, cancer and cardiovascular disease. Professor Siebert is a member
of the Harvard Flagship Initiative in Comparative Effectiveness Research, Clinical Guideline
Commissioner for the Association of the Scientific Medical Societies in Germany (AWMF) of
GMDS, a member of the Oncology Advisory Council of the Austrian Ministry of Health, Co-Chair
of the ISPOR-SMDM Modeling Task Force, and Co-Chair of the SMDM Methodology Section. He
was a member of the International Expert Committee Advising IQWiG on the Methods for
Economic Evaluations and he has served as Vice-President of SMDM and on ISPOR’s Directors
Boards. He has worked with several HTA and Government Agencies (e.g.
DAHTA@DIMDI/Germany, IQWiG/Germany, NICE/UK, ANVISA/Brazil, CADTH/Canada,
LBI-HTA/Austria, GOEG/Austria) and advises institutions regarding the conduction of HTA.
He is the author of more than 300 publications and is a member of the editorial board of several
scientific journals.
53
POSTER CATEGORIES
Posters have been arranged into the following categories and numbers:
CATEGORY
POSTER NUMBERS
Hepatitis C Virus
Diagnosis
P1–P2
Natural history and epidemiology
P3–P6
Treatment and late-stage clinical trials (Phase IIb, Phase III and Phase IV)
P7–P10
Practical management strategies
P11–P13
Treatment monitoring and predictors of therapeutic response
P14–P18
Preclinical and early clinical development (Phase I and Phase IIa)
P19–P20
Molecular biology and characterisation
P21–P22
Other
P23–P26
Hepatitis B Virus
Diagnosis and monitoring
P27
Natural history and epidemiology
P28–P29
Treatment and late-stage clinical trials (Phase IIb, Phase III and Phase IV)
P30
Practical management strategies
P31–P32
Molecular biology and characterisation
P33–P34
Other
P35–P37
Hepatocellular Carcinoma (HCC)
P38
Pharmacokinetics and Drug Interactions
P39–P41
HIV Co-infection and Viral Hepatitis
P42
Transplantation and Viral Hepatitis
P43–P44
Viral Hepatitis A, D and E
P45–P49
54
POSTER PRESENTATIONS
In all author listings, the presenting author is underlined.
HEPATITIS C VIRUS – Diagnosis
P1
The correlation between hepatitis C core antigen and HCV RNA levels with respect to
HIV status, HCV genotype and IFNL4 polymorphism
V Thong, S Akkarathamrongsin, A Avihingsanon, Y Poovorawan, P Tangkijvanich
(Bangkok, Thailand)
P2
Correlation of noninvasive serum fibrosis markers with stage of fibrosis in chronic
hepatitis
M Abdollahi, A Pouri, M Somi (Tabriz, Iran)
HEPATITIS C VIRUS – Natural history and epidemiology
P3
Prevalence of the hepatitis C virus polymorphism Q80K in a pooled analysis of G1
patients from telaprevir and simeprevir phase II/III clinical trials
C Sarrazin, E Lathouwers, M Peeters, B Daems, A Buelens, J Witek, Y Wyckmans,
B Fevery, T Verbinnen, A Ghys, M Schlag, A Baldini, S De Meyer and O Lenz (Frankfurt,
Germany)
P4
Birth cohort screening for hepatitis C: a comparative analysis in foreign-born versus USborn baby boomers
K Chudy-Onwugaje, S Yakubov, J Husney, D Benasher, C Obiagwu, S Shamah, K Teagle,
A Talasila, I Mayer, Y Tsirlin, J Park, R Rahmani (New York, USA)
P5
Epidemiological study of prevalence and risk factors for HCV among apparently healthy
Mongolians
N Dashdorj, B Dashtseren, B Bold, D Yagaanbuyant (Ulaanbaatar, Mongolia)
P6
Prevalence of HCV, HBV and HIV infections among hemophiliac
Z Khademi Mahmoodabad (Yazd, Iran)
HEPATITIS C VIRUS – Treatment and late-stage clinical trials (Phase IIb,
Phase III and Phase IV)
P7
Daclatasvir + sofosbuvir with or without ribavirin in patients with chronic HCV
infection: interim analysis of a multicenter compassionate use program
T Welzel, M Cornberg, J Petersen, K Herzer, T Berg, U Spengler, J Rockstroh, P Ingiliz,
J Wiegand, M Jimenez-Exposito, S Zeuzem (Frankfurt, Germany)
P8
Simeprevir with PegIFN/ribavirin for chronic HCV infection shortens time with patientreported symptoms and impairment in QoL: ATTAIN study results
J Scott, K Cerri, U Sbarigia, C Corbett, M Fu, W Jessner (Beerse, Belgium)
55
P9
Efficacy and safety of simeprevir in treatment-naïve HCV genotype 1-infected patients
with METAVIR F2 fibrosis: QUEST-1 and QUEST-2 Phase III studies
M Butí, M Manns, Y Horsmans, R Flisiak, G Foster, V Rafalsky, M Rizzetto,
R Sarmento-Castro, M Peeters, O Lenz, S Ouwerkerk-Mahadevan, G De La Rosa, R
Kalmeijer, M Schlag, J Witek (Barcelona, Spain)
P10
Factors associated with medical resource utilisation and related costs in treatmentexperienced patients with genotype 1 chronic hepatitis C
E Akpo, U Sbarigia, J Kleintjens (Beerse, Belgium)
HEPATITIS C VIRUS – Practical management strategies
P11
The use of silymarin in chronic hepatitis C infection: an updated systematic review and
meta-analysis
I Cua, M Oliman (Quezon City, Philippines)
P12
Factors associated with triple therapy discontinuation due to adverse effects among
patients with hepatitis C genotype 1 chronic infection
N Miotto, L Pisoni Zanaga, E Sellan L Goncales, L Mendes, M Lazarini, R Stucchi,
F Lopes Goncales Jr, A Gonzalez Vigani (Campinas, Brazil)
P13
Triple therapy with boceprevir in treatment-experienced patients with HCV in a thirdlevel hospital in Mexico
J Mata-Marín, B Manjarrez-Tellez, A Chaparro-Sánchez, G Huerta-García, J DomínguezHermosillo, J Gaytán-Martínez (Mexico City, Mexico)
HEPATITIS C VIRUS – Treatment monitoring and predictors of therapeutic
response
P14
Renal function in HCV genotype 1-infected treatment-naïve patients receiving
simeprevir in combination with Peg-IFN and ribavirin: a post-hoc analysis
S Mauss, M Butí, C Moreno, G Foster, R DeMasi, A Baldini, M Schlag, G De La Rosa,
J Witek (London, UK)
P15
The IFNL4 ΔG/TT genotyping does not improve prediction of SVR in HCV-infected
patients in the Czech Republic
S Frankova, M Jirsa, M Neroldova, R Senkerikova, P Urbanek, V Hejda, J Hubacek,
J Spicak, J Sperl (Prague, Czech Republic)
P16
Restoration of innate immune responses may be a novel therapeutic strategy for
treatment of chronic hepatitis C virus infection
Y Kishida, N Imaizumi, H Tanimura, S Kashiwamura, T Kashiwagi (Osaka City, Japan)
P17
Role of interferon lambda-4 and inosine triphosphatase polymorphisms in the
treatment of Thai patients with chronic hepatitis C virus genotype 3
S Akkarathamrongsin, V Thong, Y Poovorawan, P Tangkijvanich (Bangkok, Thailand)
56
P18
Effect of antidepressant drug use on virological response during the treatment of
chronic hepatitis C
N Tuna, S Kose, N Ozgunes, K Suer, S Celik, F Sýrmatel, N Ince, M Celen, S Tosun
(Sakarya, Turkey)
HEPATITIS C VIRUS – Preclinical and early clinical development (Phase I and
Phase IIa)
P19
IDX21437, a novel nucleotide analogue prodrug HCV NS5B polymerase inhibitor
J Sullivan-Bólyai, IDX21437 Clinical Study Team (Cambridge, USA)
P20
The effect of renal impairment on single-dose pharmacokinetics of daclatasvir, an HCV
NS5A inhibitor
T Garimella, R Wang, W Luo, C Hwang, D Sherman, H Kandoussi, T Marbury, H Alcorn,
R Bertz, M Bifano (Princeton, USA)
HEPATITIS C VIRUS – Molecular biology and characterisation
P21
Computational identification of rare codon clusters in hepatitis C virus: a bioinformatic
look
A Malekpour, H Hasani, M Fattahi, M Mortezavi (Kerman, Iran)
P22
Identification and expression profiling of microRNAs in hepatitis C patients by using
next generation sequencing
A Butt, M Idrees, Y Tong (Lahore, Pakistan)
HEPATITIS C VIRUS – Other
P23
A novel non-invasive biological predictive index (Khattab index) for liver fibrosis in
hepatitis C virus (HCV) genotype 4 patients
M Khattab, M Abd El Fattah, A Hassouna, M Sakr, M Fathy, A Elbreedy, Y Ismail,
A Osman, S Gaber, A Eltawil (Minia, Egypt)
P24
Health-Related Quality of Life and productivity impairment in chronic hepatitis C
patients in Germany
D Nouvertné, R Perry, G Milligan (Munich, Germany)
P25
Chronic hepatitis C - a 7-year experience
J Velez, A Maio, D Coutinho, S Nunes, F Freitas, O Célia (Aveiro, Portugal)
P26
Hyperlipidemia in chronic hepatitis C under triple therapy with boceprevir
J Mata-Marín, G Huerta-García, B Manjarrez-Tellez, K Andrade-Fuentes,
J Sandoval-Ramírez, M Martíinez-Rodríguez (Mexico City, Mexico)
57
HEPATITIS B VIRUS – Diagnosis and monitoring
P27
T and B cell responses and previous exposure to hepatitis B virus in "anti-HBc alone"
patients
N Semmo, Q Wang (Bern, Switzerland)
HEPATITIS B VIRUS – Natural history and epidemiology
P28
Status for hepatitis B virus infection and socioeconomic variables: a multiple
correspondence analysis
D Cadavid, D Hincapié, M Ospina, L Bernal, S Buitrago, O Pérez, E Santacruz, V Lenis,
F Díaz (Medellin, Colombia)
P29
Epidemiological study of prevalence and risk factors for HBV among apparently healthy
Mongolians
N Dashdorj, B Dashtseren, B Bold, D Yagaanbuyant (Ulaanbaatar, Mongolia)
HEPATITIS B VIRUS – Treatment and late-stage clinical trials (Phase IIb,
Phase III and Phase IV)
P30
Entecavir has high efficacy and safety in Caucasian patients with chronic hepatitis B and
co-morbidities
M Butí, R Morillas, J Pérez, M Prieto, R Solà, A Palau, M Diago, L Bonet, A Gallego,
J García-Samaniego, M Testillano, M Rodríguez, G Castellano, M Gutiérrez, M Delgado,
A Mas, M Romero-Gómez, J Calleja, A González-Guirado, J Arenas, L García-Buey,
R Andrade, A Gila (Barcelona, Spain)
HEPATITIS B VIRUS – Practical management strategies
P31
Preventing HBV reactivation: an automated prompt to remind oncologists to screen
was only partially successful
J Juan, L Hicks, L Lapointe-Shaw, J Truong, U Zurawska, K Chan, J Feld (Toronto,
Canada)
P32
Investigation of factors affecting time to initiation of hepatitis B virus treatment
D Kottler, J Casellas (London, UK)
HEPATITIS B VIRUS – Molecular biology and characterisation
P33
Molecular characterizations of hepatitis B escape mutants among blood donors in
Malaysia
S Hudu, M Ibrahim, N Harmal, A Alshrari, M Niazlin, Y Malik, Z Sekawi (Serdang,
Malaysia)
P34
Cryptic HBV, HCV and HEV infection in presumed nonA-E hepatitis
L Ganova-Raeva, Y Ben Ayed, L Punkova, D Do, H Dalton, K Yury (Atlanta, USA)
58
HEPATITIS B VIRUS – Other
P35
Evaluation of interleukin-10 gene promoter polymorphism (-819 C/T) in patients with
chronic hepatitis B virus infection
F Mirfakhar, S Mohebbi, S Hosseini, P Azimzadeh, M Zali, M Khanyaghma (Tehran, Iran)
P36
Lack of association between interleukin-27 gene polymorphisms (-964 A/G, 2905 T/G)
and chronic hepatitis B virus infection
S Mokhtari, S Mohebbi, S Hosseini, P Azimzadeh, H Mirtalebi, A Sharifian, M Zali
(Tehran, Iran)
P37
Genetic polymorphisms of interleukin-17 (rs2275913, rs2397084) and susceptibility to
chronic hepatitis B virus infection
H Tayefi, S Mohebbi, S Hosseini, P Azimzadeh, S Derakhshani, A Sharifian, M Zali
(Tehran, Iran)
HEPATOCELLULAR CARCINOMA
P38
Autophagy evaluation in chronic liver disease progression
D Molè, C Carlotto, A Kotsafti, M Minotto, R Cardin, U Cillo, F Farinati, M Bortolami
(Padua, Italy)
PHARMACOKINETICS AND DRUG INTERACTIONS
P39
Therapeutic drug monitoring of ribavirin predicts SVR and development of anemia in
boceprevir-based triple regimens
C de Kanter, D Burger (Nijmegen, The Netherlands)
P40
Anti-fibrotic effect of Smad decoy oligodeoxynucleotide in carbon tetrachlorideinduced hepatic fibrosis
K Park, J Kim, W Lee, K Kim, H An, S Lee (Daegu, South Korea)
P41
Protective effects of NF-ΚB decoy oligodeoxynucleotide on liver fibrosis through
regulation of epithelial-mesenchymal transition
K Kim, W Lee, H An, J Kim, K Park (Daegu, South Korea)
HIV CO-INFECTION AND VIRAL HEPATITIS
P42
Assessment of triple infections of HIV, TB and hepatitis (B and C); and associated risk
factors in selected district of North Wollo Zone, Ethiopia
A Woreta, A Hunegnaw, Y Yimam, A Genet, G Belay (Woldia, Ethiopia)
59
TRANSPLANTATION AND VIRAL HEPATITIS
P43
Is recipient interleukin-28B (rs12979860) polymorphism associated with clinically
recurrent HCV after living donor liver transplantation?
A Lashin, E El-Sharqawy, M Metwally, H Abd El-Raouf, E Morsy, M Sayed (Benha, Egypt)
P44
Slow response to antiviral therapy in liver transplant recipients
M Khubutia, A Salienko, V Syutkin, V Chulanov, I Karandashova, V Dolgin,
M Novruzbekov (Moscow, Russia)
VIRAL HEPATITIS A, D AND E
P45
Virological characteristics of hepatitis E and A infection in acute sporadic viral hepatitis
and acute exacerbation of chronic liver disease patients
E Gupta, N Ballani, P Pandey, S Sarin (Delhi, India)
P46
Different results of prevalence of hepatitis E specific antibodies if determined by three
EIA tests
V Nemecek, P Dite, P Smejkalova, M Maly, B Kriz (Prague, Czech Republic)
P47
Clinical burden of hepatitis E infections in Belgium
E Padalko, F Van Hoecke, T Van Maerken, L Cattoir, E Nys, I Ryckaert, M De Boulle,
A Geerts, X Verhelst, I Colle, H Van Vlierberghe (Ghent, Belgium)
P48
Acute HEV infection in liver transplant recipients: safety and efficacy of ribavirin
therapy
K Chmelova, J Sperl, E Sticova, P Trunecka, J Spicak, S Frankova (Prague, Czech Republic)
P49
Investigation of hepatitis A outbreaks at SMKN 2 Depok, West Java in October 2011
M Muslih (Jambi, Indonesia)
60
MAJORS SPONSORS
JANSSEN
Janssen is committed to improving the lives of people
impacted by hepatitis C worldwide by establishing innovative
treatment regimens that significantly improve patient
outcomes. The 2011 launch of INCIVO® (Telaprevir), a
protease inhibitor, transformed the possibility of cure for
millions of people living with hepatitis C and was built upon
our virology heritage. Now, our extensive clinical development program is focused on the
provision of new treatment options, with the aim of providing patients with an improved
chance of successful therapy and defining optimized standards of care.
Visit: www.janssen-emea.com
INDUSTRY SYMPOSIUM
17.30 – 19.00, Thursday 9 October
With experience comes wisdom: Applying the latest learnings in HCV treatment
17.30
Welcome and introduction
Stefan Zeuzem (Germany)
17.35
New treatments, new data: The ever-changing HCV landscape
Graham R Foster (UK)
17.50
Second-generation DAAs: Our experience so far
Three interactive case challenges comparing experiences in the EU vs the USA
France
Christophe Hézode (France)
Germany
Christoph Sarrazin (Germany)
USA
Nezam Afdhal (USA)
18.50
Q&A
61
MAJORS SPONSORS
GILEAD
Gilead Sciences, a research‐based biopharmaceutical company,
discovers, develops and commercialises innovative medicines
in areas of unmet medical need. Gilead’s therapeutic areas of
focus include HIV/AIDS, liver diseases, cancer and
inflammation, and serious respiratory and cardiovascular
conditions. Founded in 1987 in Foster City, California, Gilead
now employs approximately 7,000 people in offices across five continents. Over 25 years, Gilead
has become a leading biopharmaceutical company with a rapidly expanding product portfolio
and a growing pipeline of investigational drugs. With each new discovery and investigational
drug candidate, we seek to improve the care of patients living with life‐threatening diseases
around the world.
INDUSTRY SYMPOSIUM
08.30 – 10.00, Friday 10 October
Transforming HCV care – Leaving no one behind
08.30
On the fast track to cure
Stefan Zeuzem (Germany)
08.40
Paving the way to effective management of HIV/HCV co-infection
Karine Lacombe (France)
08.55
Removing HCV from the transplant equation
Kosh Agarwal (UK)
09.10
Linking care to cure in difficult-to-reach populations – PWIDs
John Dillon (UK)
09.25
Linking care to cure in difficult-to-reach populations – Prison populations
Peter Buggisch (Germany)
09.40
The road to eradication – Leaving no one behind
Panel discussion
09.50
Invited presentation: The Gilead medicines access programme
Graeme Robertson (UK)
62
MAJORS SPONSORS
ABBVIE
AbbVie is a global, research-based biopharmaceutical
company formed in 2013 following separation from Abbott.
With its 125-year history, the company’s mission is to use its
expertise, dedicated people and unique approach to
innovation to develop and market advanced therapies that
address some of the world’s most complex and serious
diseases. In 2014, AbbVie employs approximately 21,000 people worldwide and markets
medicines in more than 170 countries.
The level of AbbVie’s sponsorship is €115,118.15 (exchange rate at time of contract signature)
INDUSTRY SYMPOSIUM
18.20 – 19.50, Friday 10 October
Current and emerging IFN-free HCV treatment options: defining simplicity
18.20
Welcome and Introduction: what do we mean by “one size fits all”?
Ira Jacobson (USA)
18.30
Winners and losers: the evolution of factors affecting current and emerging HCV
treatment outcomes and treatment decisions
Kris Kowdley (USA)
19.00
HCV treatment outcomes in special populations; can “one size” ever be enough?
Graham Foster (UK)
19.30
Q&A and Summary
Stefan Zeuzem (Germany)
63
MAJORS SPONSORS
BRISTOL-MYERS SQUIBB
Bristol-Myers Squibb is a global biopharmaceutical company
whose mission is to discover, develop and deliver innovative
medicines that help patients prevail over serious diseases. Our
medicines are helping millions of people around the world in
their fight against cancer, cardiovascular disease, hepatitis B
and C, HIV/AIDS and rheumatoid arthritis.
INDUSTRY SYMPOSIUM
08.30 – 10.00, Saturday 11 October
A step closer to solving the puzzle: how different HCV drug classes fit together to provide
cure
08.30
Welcome and introduction
Stefan Zeuzem (Germany)
08.35
Hepatitis C treatment solutions here and now: decoding the latest approved
European therapies
Heiner Wedemeyer (Germany)
08.50
Solving the riddle of advanced hepatitis C disease: a case by case approach
Jürgen Rockstroh (Germany); Vincent Leroy (France); Kosh Agarwal (UK)
09.35
The final analysis: panel debate
Stefan Zeuzem (Germany); Kosh Agarwal (UK); Vincent Leroy (France); Patrick Marcellin
(France); Jürgen Rockstroh (Germany); Heiner Wedemeyer (Germany)
09.55
Summary and close
Patrick Marcellin (France)
64
PRE-CONGRESS WORKSHOP SPONSOR
ACHILLION
Achillion is an innovative pharmaceutical company focused on
developing best-in-class compounds and advancing
commercially-competitive, short-duration treatment regimens
for Hepatitis C Virus (HCV) infection that are once-daily and
ribavirin-free. Achillion’s portfolio of direct acting HCV
antivirals includes ACH-3422, our novel nucleotide NS5B RNA
polymerase inhibitor currently in Phase 1b clinical development, ACH-3102, a 2nd Generation
NS5A Inhibitor with pico-molar potency and pan-genotypic HCV activity in vitro, currently in
Phase 2 clinical trials and sovaprevir (ACH-1625), a NS3/4A protease inhibitor in phase 2 with
growing clinical experience with 200mg once daily. Founded in 2000 and headquartered in New
Haven, CT, Achillion is dedicated to bringing important new treatments to patients.
PRE-CONGRESS WORKSHOP
11.30 – 12.30, Thursday 9 October
Nucleotide-Containing HCV Treatment Regimens: Efficacy, Safety, Resistance, Genotype
and Treatment Duration Considerations
11.30
The evolving HCV treatment landscape and overview of nucleotide NS5B inhibitors
Ira M Jacobson (USA)
11.50
Efficacy and safety of nucleotide and non-nucleotide inhibitor regimens in HCV
Christoph Sarrazin (Germany)
12.10
Discussion and Q&A: Key differences between and advantages of nucleotide
regimens in HCV. Where do we go from here?
Ira M Jacobson (USA); Christoph Sarrazin (Germany)
12.25
Summary
Ira M Jacobson (USA)
65
EXHIBITOR
Alongside exhibitions from the four Major Sponsors, we are pleased to welcome:
MP BIOMEDICALS
MP Biomedicals is a worldwide corporation headquartered in
Southern California, with ISO-certified and FDA-approved
manufacturing and distribution facilities throughout the
globe. MP Biomedicals manufactures and sells more than
55,000 products and is one of the only companies in the
industry to offer a comprehensive line of life science, fine
chemical and diagnostic products. MP Biomedicals has a long-standing history of marketing
high-quality diagnostic products, including Western blots, ELISAs, rapid tests and analyzer
solutions. All MP Diagnostics products are produced under the strictest regulatory standards at
our worldwide facilities. A vast network of global distributors, satellite facilities and offices
throughout Europe, Asia, Australia and the Americas ensures product delivery whenever and
wherever needed.
OTHER SPONSORS
POSTER AREA SPONSOR
BADGE AND LANYARD SPONSOR
66
AUTHOR INDEX
Abd El Fattah, M
P23
Burger, D
O218*, P39
Abd El-Raouf, H
P43
Butí, M
Abdollahi, M
P2*
O234*, O21CH1,
P9*, P14, P30*
Abdurakhmanov, D
O213
Butt, A
P22*
Abou El Azm, A
O113
Cadavid, D
P28*
Afdhal, N
O111*, O23CH
Calleja, J
P30
Akkarathamrongsin, S
P1, P17
Calmus, Y
O314
Akpo, E
P10
Cardin, R
P38
Alcorn, H
P20
Carlotto, C
P38
Alshrari, A
P33
Carpentier, A
O314
Alter, H
OL1*
Casellas, J
P32
An, H
P40, P41
Castellano, G
P30
Andrade, R
P30
Catanese, M
O231
Andrade-Fuentes, K
P26
Cattoir, L
P47
Aoudjehane, L
O314
Celen, M
P18
Arenas, J
P30
Célia, O
P25
Asselah, T
O311*
Celik, S
P18
Avihingsanon, A
P1
Cerri, K
P8
Azimzadeh, P
P35, P36, P37
Chan, K
P31
Baldini, A
P3, P14
Chaparro-Sánchez, A
P13
Ballani, N
P45
Chi, H
O232
Baruch, Y
O213
Chmelova, K
P48*
Belay, G
P42
Chudy-Onwugaje, K
P4*
Ben Ayed, Y
P34
Chulanov, V
P44
Benasher, D
P4
Cillo, U
P38
Berenguer, M
O217*, O221*,
KL2CH, O31CH
Colle, I
P47
Colombo, M
KL1*
Berg, T
P7
Conti, F
O314
Bernal, L
P28
Corbett, C
P8
Bertz, R
P20
Cornberg, M
P7
Bifano, M
P20
Coutinho, D
P25*
Bold, B
P5, P29
Craxì, A
KL2CH, O31CH
Bonet, L
P30
Cua, I
P11
Bortolami, M
P38
Daems, B
P3
Bourlière, M
O123*
Dalton, H
P34
Bruck, R
O213
Dammacco, F
O323*
Buelens, A
P3
Dammers, E
O212
Buitrago, S
P28
* Denotes presenting author
67
Dashdorj, N
P5*, P29*
Fu, M
O212, P8
Dashtseren, B
P5, P29
Gaber, S
P23
De Boulle, M
P47
Gadano, A
O213
de Kanter, C
P39*
Gallego, A
P30
De La Rosa, G
P9, P14
Ganova-Raeva, L
P34*
de Launoit, Y
O314
García-Buey, L
P30
De Meyer, S
P3
García-Samaniego, J
P30
Delgado, M
P30
Garimella, T
P20
Delhem, N
O314
Gaytán-Martínez, J
P13
DeMasi, R
P14
Geerts, A
P47
Derakhshani, S
P37
Genet, A
P42
Diago, M
O213, P30
George, J
O212
Díaz, F
P28
Ghys, A
P3
Dite, P
P46
Gila, A
P30
Do, D
P34
Gonzalez Vigani, A
P12
Dolgin, V
P44
González-Guirado, A
P30
DomínguezHermosillo, J
P13
Gupta, E
P45*
Gutiérrez, M
P30
Dorner, M
O231*
Hairwadzi, H
O235
Dubuisson, J
O314
Harmal, N
P33
Dusheiko, G
O216*, O22CH
Hasani, H
P21
El Kassa, G
O113
Hassouna, A
P23
Elbreedy, A
P23
Hejda, V
P15
Elhendawy, M
O113*
Herzer, K
P7
El-Sharqawy, E
P43
Hicks, L
P31
Eltawil, A
P23
Hincapié, D
P28
Farinati, F
P38
Hinrichsen, H
O212*
Fathy, M
P23
Horban, A
O212
Fattahi, M
P21
Horsmans, Y
P9
Feld, J
O322*, P31
Hosseini, S
P35, P36, P37
Ferenci, P
O213
Hubacek, J
P15
Fevery, B
P3
Hudu, S
P33*
Finkelmeier, F
O113
Huerta-García, G
P13, P26*
Flisiak, R
O213, P9
Hughes, D
O231
Foster, G
O121*, P9, P14*
Hughes, E
O213
Frankova, S
P15*, P48
Hunegnaw, A
P42
Freitas, F
P25
Husney, J
P4
Fried, M
O211*, O21CH2
Hwang, C
P20
* Denotes presenting author
68
Ibrahim, M
P33
Kowdley, K
O215*, KL3CH,
O32CH
Idrees, M
P22
IDX21437 Clinical Study P19
Team
Kriz, B
P46
Kurland, D
O212
Imaizumi, N
P16
Lapointe-Shaw, L
P31
Ince, N
P18
Large, E
O231
Ingiliz, P
P7
Lashin, A
P43
Ismail, Y
P23
Lathouwers, E
P3
Jacobson, I
KL1CH, O213*,
O312*, OLCH,
O11CH
Lazarini, M
P12
Lee, S
P40
Lee, W
P40, P41
Janczewska, E
O213
Lenis, V
P28
Janssen, H
O232*
Lenz, O
O212, P3, P9
Jessner, W
O212, P8
Lopes Goncales Jr, F
P12
Jimenez-Exposito, M
P7
Lueth, S
O213
Jirsa, M
P15
Luo, W
P20
Juan, J
P31*
Lussignol, M
O231
Kalmeijer, R
P9
Maio, A
P25
Kandoussi, H
P20
Malekpour, A
P21
Karandashova, I
P44
Malik, Y
P33
Kashiwagi, T
P16
Maly, M
P46
Kashiwamura, S
P16
Manjarrez-Tellez, B
P13, P26
Kgatle, M
O235*
Manns, M
P9
Khademi
Mahmoodabad, Z
P6*
Marbury, T
P20
Marcellin, P
O233*, O21CH1
Khanyaghma, M
P35
Martíinez-Rodríguez, M P26
Khattab, M
P23*
Martin, P
O223*, O23CH
Khubutia, M
P44
Mas, A
P30
Kim, J
P40, P41
Mata-Marín, J
P13*, P26
Kim, K
P40, P41
Mauss, S
P14
Kishida, Y
P16*
Mayer, I
P4
Kleintjens, J
P10
McPhee, F
O213
Knysz, B
O213
Mendes, L
P12
Köberle, V
O113
Metwally, M
P43*
Kopit, J
O213
Michener, T
O213
Kose, S
P18
Milligan, G
P24
Kotsafti, A
P38
Minotto, M
P38
Kottler, D
P32*
Miotto, N
P12*
* Denotes presenting author
69
Mirfakhar, F
P35
Perry, R
P24
Mirtalebi, H
P36
Petersen, J
P7
Mohebbi, S
P35*, P36*, P37*
Piiper, A
O113
Mokhtari, S
P36
Pisoni Zanaga, L
P12
Molè, D
P38*
Poovorawan, Y
P1, P17
Moradpour, D
KL3*
Pouri, A
P2
Morales, O
O314
Prieto, M
P30
Moreno, C
P14
Punkova, L
P34
Morillas, R
P30
Rafalsky, V
P9
Morsy, E
P43
Rahmani, R
P4
Mortezavi, M
P21*
Reddy, K
O212
Muslih, M
P49*
Reesink, H
O12CH
Negro, F
O321*
Rizzetto, M
P9
Nelson, D
O214*, O21CH2
Rockstroh, J
P7, O222*
Nemecek, V
P46*
Rodríguez, M
P30
Neroldova, M
P15
Romero-Gómez, M
P30
Niazlin, M
P33
Ryckaert, I
P47
Nouvertné, D
P24*
Safadi, R
O213
Noviello, S
O213
Sakr, M
P23
Novruzbekov, M
P44
Salienko, A
P44
Nunes, S
P25
Sandoval-Ramírez, J
P26
Nys, E
P47
Santacruz, E
P28
Obiagwu, C
P4
Sarin, S
P45
Oliman, M
P11*
Sarmento-Castro, R
P9
Osman, A
P23
Sarrazin, C
Ospina, M
P28
O112*, O113, P3*,
KL3CH, O32CH
Ouaguia, L
O314*
Sayed, M
P43
OuwerkerkMahadevan, S
O212, P9
Sbarigia, U
P8*, P10*
Sceats, E
O231
Ozgunes, N
P18
Schlag, M
O212, P3, P9, P14
Padalko, E
P47*
Schooley, R
O122*, O22CH
Palau, A
P30
Scott, J
P8
Pandey, P
P45
Sekawi, Z
P33
Park, J
P4
Sellan L Goncales, E
P12
Park, K
P40*, P41*
Semmo, N
P27*
Peeters, M
P3, P9
Senkerikova, R
P15
Pérez, J
P30
Shafran, S
O213
Pérez, O
P28
Shamah, S
P4
* Denotes presenting author
70
Sharifian, A
P36, P37
Velez, J
P25
Sherman, D
P20
Verbinnen, T
O212, P3
Siebert, U
KL2*, O12CH
Verhelst, X
P47
Smejkalova, P
P46
Villamil, F
O212
Solà, R
P30
Vivekanandan, P
O235
Somi, M
P2
Wai, S
O231
Spengler, U
P7
Waidmann, O
O113
Sperl, J
P15, P48
Wang, Q
P27
Spicak, J
P15, P48
Wang, R
P20
Stanciu, C
O212
Wedemeyer, H
O313*
Sticova, E
P48
Weiland, O
O212
Stucchi, R
P12
Welzel, T
P7*
Suer, K
P18
Wiegand, J
P7
Sullivan-Bólyai, J
P19*
Witek, J
P3, P9, P14
Susser, S
O113
Woreta, A
P42*
Sýrmatel, F
P18
Wychowski, C
O314
Syutkin, V
P44*
Wyckmans, Y
P3
Talasila, A
P4
Yagaanbuyant, D
P5, P29
Taliani, G
O212
Yakubov, S
P4
Tangkijvanich, P
P1*, P17*
Yimam, Y
P42
Tanimura, H
P16
Yin, P
O213
Tayefi, H
P37
Yury, K
P34
Teagle, K
P4
Zali, M
P35, P36, P37
Testillano, M
P30
Zarebska-Michaluk, D
O213
Thabut, D
O213
Zeuzem, S
Thompson, A
O213
Thong, V
P1, P17
KL1CH, O113,
O212, O213, OLCH,
O11CH, P7
Thursz, M
O231
Zignego, A
O213
Tong, Y
P22
Zoulim, F
O212
Tosun, S
P18
Zurawska, U
P31
Trunecka, P
P48
Truong, J
P31
Tsirlin, Y
P4
Tuna, N
P18*
Urbanek, P
P15
Van Hoecke, F
P47
Van Maerken, T
P47
Van Vlierberghe, H
P47
* Denotes presenting author
71
Produced by KnowledgePoint360 Group, an Ashfield Company
Victoria Mill, Windmill Street
Macclesfield, Cheshire SK11 7HQ, UK
Copyright © 2014 KnowledgePoint360 Group. All rights reserved.
72